Relationship between In Vitro Chemosensitivity assessed with MTT Assay and Clinical Outcomes in 103 Patients with Acute Leukemia

Abstract

Background : Cellular drug resistance is supposed to play a major role in chemotherapy failure or relapse. The purpose of this study was to analyze the relationship between in vitro chemosensitivity test results using a 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and clinical response on chemotherapy, and to find the possibility of optimizing the treatment protocol for individual patients according to their actual drug resistance.Methods : For MTT assay, we obtained bone marrow aspirates from 103 patients with acute leukemia at the time of initial diagnosis or relapse. The following drugs were tested: cytarabine, vincristine, methotrexate, daunorubicin, dexamethasone, L-asparaginase, and mitoxantrone. To evaluate clinical responses after induction chemotherapy, we followed up on their bone marrow study.Results : In our study, in vitro chemosensitivity test with the MTT assay significantly predicted whether patients with AML remained continuous complete remission or went into relapse. It also predicted whether or not child patients with ALL would acquire complete remission after induction chemotherapy.Conclusions : Although it does not provide the insight into the mechanisms that cause drug resistance, the MTT assay may be a useful tool in individually optimizing the chemotherapy of patients with acute leukemia. (Korean J Lab Med 2007;27:89-95)

Mitogen-Activated Protein Kinase 2 Relevance for the in-vitro Chemo-Sensitivity and Clinical Response in Children with Acute Lymphoblastic Leukemia in Mansoura University Hospitals

“…In vitro drug resistance to each of the four chemotherapeutics agents used was associated with worse outcome after combination therapy and refractory disease. These results came in accordance with those of (Jun et al, 2007) study that predicted the occurrence of complete remission after induction chemotherapy in children with ALL by the aid of the MTT in vitro chemo-sensitivity assay.…”

“…The Methyl Thiazolyl Tetrazolium (MTT) in vitro chemo-sensitivity assay on cultured leukemic cells had been reported to have high sensitivity (about 90 %) and high specificity (about 80 %), as well false negative result was not detected (Dogan et al, 2004;Jun et al, 2007). Using in vitro chemo-sensitivity assay test in arrangement with information from molecular profiling can afford a fuller picture about the nature of individual disease.…”

Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity

“…Accordingly, an efficient ex vivo chemosensitivity test could be of enormous benefit in such an identification, and would also help in selecting alternative drugs that could potentially improve the response rate and minimise toxicity. Despite the great efforts in developing chemosensitivity tests for many years and the promising results obtained in tailored trials to validate their use in clinical practice, there remains a lack of actionable, robust tests that can be readily used to guide therapeutic decisions in routine practice (Jun et al , ). In this way, we detected patients that despite having multiresistance show sensitivity to other drugs such as clofarabine (Clo) and fludarabine (Flu), as alternative therapies.…”

Результаты Индивидуализированной Химиотерапии У больных Саркомой Мягких Тканей

“…Таким образом, некоторые авторы показали преимущества методов персонифицированного определения химиочувствительности перед стандартной химиотерапией и, опираясь на высокую корреляцию культуральных ответов с клиническими (реакция опухолей, протяженность безрецидивного и общего выживания), высказались в поддержку развития методов таргетированного подхода [7,13,14,16,22,25,26]. Другие исследователи не смогли выявить преимуществ методов индивидуальной оценки химиочувствительности перед протокольными и заняли отрицательную позицию [27,28]…”